How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,010 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Clinical features and outcomes of COVID-19 patients with benign prostatic hyperplasia in ageing male: A retrospective study of 18 cases. Full Text available with Trip Pro

Clinical features and outcomes of COVID-19 patients with benign prostatic hyperplasia in ageing male: A retrospective study of 18 cases. A worldwide pandemic of coronavirus disease 2019 (COVID-19) which emerged in China in December 2019 affects the world very seriously. We aimed to evaluate the benign prostatic hyperplasia (BPH) patients who were admitted and treated to our hospital due to COVID-19.Between March 18, 2020 and April 5, 2020, 18 patients admitted with COVID-19 who has BPH

2020 International journal of clinical practice

82. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. (Abstract)

Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. Several newer medications have emerged for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). The efficacy/safety of PDE-5 inhibitors (Tadalafil 5 mg) in BPH-lower urinary tract symptoms (LUTS) has been sparingly assessed in the published English literature as compared

2020 International journal of clinical practice

83. Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain. Full Text available with Trip Pro

Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain. To describe the real-world demographic and clinical characteristics of patients with lower urinary tract symptoms (LUTS) as a result of benign prostatic hyperplasia (BPH) in Spain.This observational, retrospective, multicentre study conducted in primary care and urology clinics in Spain included men aged ≥50 years diagnosed (≤8 years prior to study visit (...) ) with LUTS caused by BPH. The primary endpoint was demographic and clinical characteristics; secondary endpoints included disease progression and diagnostic tests across both healthcare settings.A total of 670 patients were included (primary care: n = 435; urology: n = 235). Most patients had moderate/severe LUTS (74.6%) and prostate volume >30 cc (81.7%), with no differences between settings. More patients had prostate-specific antigen (PSA) ≥1.5 ng/mL in primary care (74.5%) versus urology (67.7

2020 International journal of clinical practice

84. Statewide Price Variation for Generic Benign Prostatic Hyperplasia Medications. (Abstract)

Statewide Price Variation for Generic Benign Prostatic Hyperplasia Medications. To examine the geographic and pharmacy-type variation in costs for generic benign prostatic hyperplasia (BPH) medications in order to improve drug price transparency and reduce health disparities. Medical therapy for BPH can be expensive, having significant implications for uninsured and underinsured patients.We generated a 20% random sample of all pharmacies in Pennsylvania and queried each for the uninsured cash

2020 Urology

85. Does Symptomatic Benign Prostatic Hyperplasia Increase the Risk of Periprosthetic Joint Infection After Primary Total Joint Arthroplasty? (Abstract)

Does Symptomatic Benign Prostatic Hyperplasia Increase the Risk of Periprosthetic Joint Infection After Primary Total Joint Arthroplasty? Periprosthetic joint infection (PJI) is among the leading causes of failure in total joint arthroplasty. A recently proposed risk factor for PJI is symptomatic benign prostatic hyperplasia (sBPH). This study aims to determine if sBPH is associated with PJI following primary total hip arthroplasty (THA) and total knee arthroplasty (TKA).Using the Mariner all

2020 Journal of Arthroplasty

86. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). (Abstract)

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). PLUS investigated the efficacy and safety of mirabegron add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying lower urinary tract symptoms attributable to benign prostatic hyperplasia.In this phase 4 study a 4-week 0.4 mg tamsulosin run-in period (...) of PLUS underscore the utility of mirabegron add-on therapy to treat men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia.

2020 Journal of Urology

87. Disparities in Benign Prostatic Hyperplasia Progression: Predictors of Presentation to the Emergency Department in Urinary Retention. (Abstract)

Disparities in Benign Prostatic Hyperplasia Progression: Predictors of Presentation to the Emergency Department in Urinary Retention. This retrospective cohort study evaluates the characteristics of patients who presented to the emergency department with acute urinary retention.Using the Healthcare Cost and Utilization Project State Emergency Department Databases we conducted a retrospective cohort study of patients who presented to emergency departments in Florida between 2005 and 2015. Male (...) patients age 45 years or older who presented with diagnosis codes for acute urinary retention and lower urinary tract symptoms/benign prostatic hyperplasia were considered. Information was collected on age, race/ethnicity, primary insurance and rural-urban commuting area codes.The mean age for males presenting with acute urinary retention was 72.2 years, which was 10.6 years older than those presenting for nonurological complaints (p <0.001). Multivariable analysis adjusted for measured confounders

2020 Journal of Urology

88. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. (Abstract)

High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. Although clinical trials demonstrate 5-alpha reductase inhibitors are efficacious treatments for benign prostatic hyperplasia, they have low reported medication adherence outside of clinical trials. We evaluated real-world drug adherence and clinical outcomes in Medicare patients with lower urinary tract symptoms from benign prostatic (...) hyperplasia managed with 5-alpha reductase inhibitor therapy.Using health care and pharmacy claims from Partners Healthcare Medicare Accountable Care Organization enrollees (January 2009 to July 2018), we identified men initiating a 5-alpha reductase inhibitor for benign prostatic hyperplasia with more than 1 medication dispensation. Adherence was calculated as an 80% or greater proportion of days covered. A Cox proportional hazards model was used to evaluate the primary outcome of treatment failure

2020 Journal of Urology

89. Noninvasive Pressure Flow Studies in the Evaluation of Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Review of 50,000 Patients. (Abstract)

Noninvasive Pressure Flow Studies in the Evaluation of Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Review of 50,000 Patients. The UroCuff® Test is a noninvasive pressure flow study used to manage men with lower urinary tract symptoms. UroCuff Tests were performed on men with lower urinary tract symptoms to evaluate voiding characteristics and quantify changes in urodynamic parameters with age.This cross-sectional study included all UroCuff Tests performed

2020 Journal of Urology

90. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. Full Text available with Trip Pro

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. The AUA Guideline panel provides evidence-based recommendations for the surgical management of male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).The Panel amended the Guideline in 2020 to reflect additional literature published through September 2019. When sufficient evidence existed, the Panel assigned the body of evidence (...) statement (Guideline 15) with updated supporting text for prostatic urethral lift (PUL); 4) an amended statement (Guideline 16) for PUL; 5) an amended statement (Guideline 17) with updated supporting text for transurethral microwave therapy (TUMT); 6) an amended statement (Guideline 18) with updated supporting text for water vapor thermal therapy; 7) updated supporting text for water vapor thermal therapy (Guideline 19); 8) an amended statement (Guideline 21) with updated supporting text for laser

2020 Journal of Urology

91. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. (Abstract)

Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. Our current understanding of recent trends in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia is incomplete, particularly in younger men. The 2018 Urologic Diseases in America Project attempted to fill this gap by analyzing multiple large administrative claims databases which include men of all ages and permit (...) longitudinal followup. To our knowledge we report these findings for the first time in the scientific literature.The 2 data sources used in this study included the de-identified Optum® Clinformatics® Data Mart database for men 40 to 64 years old and the Medicare 5% Sample for men 65 years old or older. To assess trends in lower urinary tract symptoms/benign prostatic hyperplasia related medication prescriptions and surgical procedures from 2004 to 2013 we created annual cross-sectional cohorts

2020 Journal of Urology

92. A Claims-based Assessment of Reoperation and Acute Urinary Retention After Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia. (Abstract)

A Claims-based Assessment of Reoperation and Acute Urinary Retention After Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia. To evaluate real-world utilization of common transurethral prostate procedures in the ambulatory surgical setting and compare subsequent rates of treatment failure.Using the New York Statewide Planning and Research Cooperative System database we identified men ≥40 years old undergoing ambulatory surgeries categorized as transurethral resection (...) of the prostate (TURP), photoselective vaporization of the prostate (PVP), endoscopic enucleation, or other (transurethral incision, microwave/radiofrequency ablation) from 2010-2016. Multivariate Cox proportional hazards regression was used to predict treatment failure, defined as reoperation or postoperative acute urinary retention >30 days post-procedure.We identified 15,982 men, median age 69 years (IQR: 63-76), 61% of whom underwent PVP, 36% TURP, 1.5% endoscopic enucleation, and 1.5% other transurethral

2020 Journal of Urology

93. Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day. (Abstract)

Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day. Alpha-adrenergic antagonist treatment for benign prostatic hyperplasia (BPH) and drug-related sexual side effects are frequent in aging men.To investigate functional changes in erectile and ejaculatory aspects of male sexuality under Silodosin 8 mg per day treatment for BPH.Sexually active patients diagnosed with BPH and who initiated Silodosin treatment were (...) to follow-up after drug initiation have limited our interpretation.Most patients using Silodosin 8 mg per day for BPH treatment experienced improvement in their erectile function, estimated IELT, and premature ejaculation profile in the third month of the treatment. Underlying mechanisms and reasons for individual differences necessitate further investigation. Cihan A, Kazaz İO, Yıldırım Ö, et al. Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia

2020 Journal Of Sexual Medicine

94. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. Full Text available with Trip Pro

Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. In the last decade, many novel minimally invasive surgical techniques within benign prostatic hyperplasia (BPH) surgery were developed to reduce postoperative complications that often discourage patients from pursuing BPH surgery.To assess perspective of future and past international BPH surgery patients regarding their postoperative complications, namely erectile and ejaculatory function.A survey (...) sexual outcomes such as Rezum and UroLift for prostates <80 mL, and Aquablation for any size prostate are available, more research is needed to investigate their long-term effects on sexual function before they can be recommended to patients. Bouhadana D, Nguyen D-D, Zorn KC, et al. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. J Sex Med 2020;17:2108-2112.Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

2020 Journal Of Sexual Medicine

95. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273) Overview | Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | Guidance | NICE Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) Technology appraisal [TA273] Published date: 23 January 2013 Share Guidance NICE is unable to recommend the use in the NHS of tadalafil (...) for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology. Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

96. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review

Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 178. 2016 Authors' objectives To assess the efficacy, comparative effectiveness, and adverse

2016 Health Technology Assessment (HTA) Database.

97. Aconiti Lateralis Radix Preparata, the Dried Root of <i>Aconitum carmichaelii</i> Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis. Full Text available with Trip Pro

Aconiti Lateralis Radix Preparata, the Dried Root of Aconitum carmichaelii Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis. Benign prostatic hyperplasia (BPH) is a common disease in elderly men which can be characterized by an abnormal enlargement of the prostate associated with lower urinary symptoms. Current medications available for BPH treatment display several adverse effects; thus, the search for effective (...) treatments with less side effects is still ongoing. In this study, we investigated the effect of Aconiti Lateralis Radix Preparata (dried root of Aconitum carmichaelii Debx.; AL), which is an herb used to treat extremely cold symptoms in traditional Korean medicine, on BPH using a testosterone propionate- (TP-) induced BPH rat model. Eight-week inguinal injection of TP induced BPH in rats, the prostate of which was displaying an abnormal proliferation. The pathological proliferation of the prostate

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

98. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. (Abstract)

Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. The benign prostatic syndrome, comprising lower urinary tract symptomatology secondary to benign prostatic hyperplasia/enlargement, represents a major health care issue in westernized countries. The pharmacological management involves alpha-adrenoceptor antagonists, intervention into the hormonal control of prostate growth using inhibitors of the enzyme 5-alpha-reductase (...) /antagonists of endogenous peptides, botulinum toxin, NX-1207), the steroidal axis (cetrorelix) or the metabolic turn-over (lonidamine), as well as the combination of drugs already established in the treatment of lower urinary tract symptomatology/benign prostatic hyperplasia (phosphodiesterase 5 inhibitor plus alpha-adrenoceptor antagonist).Many research efforts have provided the basis for the development of new therapeutic modalities for the management of lower urinary tract dysfunctions, some of which

2019 World journal of urology

99. Effects of poloxamer-based thermo-sensitive sol-gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, single-blinded, randomised controlled trial. Full Text available with Trip Pro

Effects of poloxamer-based thermo-sensitive sol-gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, single-blinded, randomised controlled trial. To evaluate the effectiveness of poloxamer-based thermo-sensitive sol-gel instillation, after transurethral resection of the prostate (TURP), for preventing urethral stricture.In all, 198 patients underwent TURP for benign prostatic hyperplasia. Recruited patients were randomly (...) divided into two groups: groups A and B. Patients in Group A (100 patients, experimental group) received poloxamer-based thermo-sensitive sol-gel instillation and patients in the Group B (98 patients, control group) received lubricant instillation after TURP. Each patient was evaluated at 4 (V1), 12 (V2), and 24 weeks (V3) after TURP. The effectiveness of poloxamer-based thermo-sensitive sol-gel instillation was evaluated based on the International Prostate Symptom Score (IPSS), IPSS-Quality of Life

2019 BJU international Controlled trial quality: uncertain

100. WATER vs WATER II: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30cc-80cc and 80cc-150cc Prostates. Full Text available with Trip Pro

WATER vs WATER II: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30cc-80cc and 80cc-150cc Prostates. Surgical options, especially those with short learning curves are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AQUABEAM System, PROCEPT BioRobotics, Inc., USA) could be this novel tool with global reproducibility, independent of prostate volume. We compared the outcomes of Aquablation (...) in 30cc to 80cc prostates with those in 80cc to 150cc.WATER (NCT02505919) is a prospective, double-blind, multicenter, international clinical trial comparing Aquablation and TURP for the treatment of LUTS/BPH in prostates between 30cc and 80cc. WATER II (NCT03123250) is a prospective, multicenter, single-arm international clinical trial of Aquablation in prostates between 80cc and 150cc. We compare baseline parameters and 12-month outcomes in 116 WATER (W-I) and 101 WATER II (W-II) study subjects

2019 BJU international

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>